Neil Versel is an editor at GenomeWeb. He covers the life science and healthcare informatics markets.
The California health system has expanded its partnership with CancerIQ to integrate risk assessment and oncology patient management into its EHR.
Standards for interoperability and better cooperation among stakeholders will help unleash the power of genomics in cancer care, says the head of the Biden Cancer Initiative.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.
With $50 million from Japanese firm NEC, biomedical software startup BostonGene seeks to assess patients' "immune fitness" in the quest for better therapies.
The year-old Princess Máxima Center, based in Utrecht, has turned to bioinformatics firm The Hyve to address integration and interoperability issues.
Symbolized by its first time exhibiting at HIMSS, Roche Diagnostics is using data to bridge the worlds of imaging, sequencing, diagnostics, drug discovery, and treatment.
City of Hope and Texas Oncology are the first customers for Trapelo, a decision support platform from Innovation Insights that involves labs and payors.
The new multinational consortium, backed by the EU and Canada, seeks to improve understanding of immune responses and uncover new therapeutic targets.
After raising $320M in venture capital, Tempus hopes to sequence 100,000 samples in 2019 as it expands its precision medicine program into depression and diabetes.
Informaticians at Spain's National Cancer Research Centre develop a methodology for evaluating likely drug efficacy based on specific patient genotypes.